Last Updated : October 30, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Vyvgart | efgartigimod alfa | Generalized myasthenia gravis (gMG) | Reimburse with clinical criteria and/or conditions | Complete | ||
Vyxeos | daunorubicin and cytarabine | Acute myeloid leukemia | Reimburse with clinical criteria and/or conditions | Complete | ||
Vyzulta | latanoprostene bunod | Open-angle glaucoma or ocular hypertension | Reimburse with clinical criteria and/or conditions | Complete | ||
Wainua | eplontersen | Polyneuropathy in hereditary transthyretin-mediated amyloidosis | Active | |||
Wakix | pitolisant hydrochloride | Narcolepsy | Do not reimburse | Complete | ||
Waymade-Trientine | trientine hydrochloride | Wilson's Disease | Reimburse with clinical criteria and/or conditions | Complete | ||
Wegovy | semaglutide | Weight management | Do not reimburse | Complete | ||
Wegovy | semaglutide | weight management | Pending | |||
Welireg | belzutifan | von Hippel-Lindau disease-associated tumours | Reimburse with clinical criteria and/or conditions | Complete | ||
Welireg | belzutifan | advanced renal cell carcinoma (RCC) | Pending |